anti-PD-1 antibody-Chinese PLA General Hospital-solid tumor

The **anti-PD-1 antibody-Chinese PLA General Hospital-solid tumor** refers to an investigational monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, utilized by the Chinese PLA General Hospital in clinical research for the treatment of advanced solid tumors. As a checkpoint inhibitor, it functions by blocking the interaction between PD-1 on T cells and its ligands (PD-L1 and PD-L2) on tumor cells, thereby preventing the suppression of T-cell activity and enhancing the immune system's ability to recognize and destroy cancer cells. In specific clinical protocols, such as those evaluating the KRAS-EphA-2-CAR-DC vaccine, this antibody is administered intravenously to provide synergistic anti-tumor effects in patients with locally advanced or metastatic solid tumors, particularly those harboring KRAS mutations.

Other names

anti-PD-1 antibodyanti-PD1 antibodyanti-PD 1 antibodyProgrammed cell death protein 1 antibody